App-Quantinova.ai

Drug Resistance, Basal Core Promoter and Pre-Core Stop Mutations in a Large Cohort of North American Children With Hepatitis B: Results for the Pediatric Cohort Study of the NIDDK-Sponsored Hepatitis B Research Network (HBRN)

Simon Ling - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

N/A

Predictors of Antiviral Therapy Initiation in Chronic Hepatitis C (HCV)

Terry Lee - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatitis C

Boceprevir

Long Term Follow-Up of Patients Treated With Sofosbuvir in the Phase 3 Studies Fission, Positron, Fusion and Neutrino

Stephen D. Shafran - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sofosbuvir

Effect of HCV Genotype-1 Subtype on Response to Faldaprevir Plus Pegylated Interferon ?-2A and Ribavirin in Treatment-NaiVE Patients: Pooled Data From Phase III Trials

Donald M. Jensen - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Faldaprevir-sodium

Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates ?90% in Treatment-NaiVE Adults Infected With Hepatitis C Virus Genotype 1A

Jacob Lalezari - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hepatitis C

Ritonavir

Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-NaiVE Patients With Chronic Hepatitis C Genotype-1 Infection: a Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2)

Graham Foster - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

interferon alfa-2a

Virological Response in Treatment-NaiVE Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon ?-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction

Donald M. Jensen - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Faldaprevir-sodium

Early Stopping Rules for Faldaprevir Plus Pegylated Interferon ?-2A and Ribavirin in Treatment-NaiVE Patients: Exploratory Study of Pooled Data From Phase III Trials

Douglas T. Dieterich - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Faldaprevir-sodium

Comparisons of Populations in Faldaprevir Phase III Studies Based on Pegylated Interferon ?-2A and Ribavirin-Predicted Responsiveness and Impact on Achieving Svr12

Donald M. Jensen - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Faldaprevir-sodium

Pharmacokinetics of Laquinimod in Patients With Active Moderate to Severe Crohn's Disease

William Sandborn - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Multiple Sclerosis

N/A

Reduction of Fecal Calprotectin and Clinical Symptoms in the Phase 2 Study of Laquinimod for the Treatment of Active Moderate-to-Severe Crohn's Disease

William Sandborn - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Identified Areas of Need to Enhance Evidence-Based Inflammatory Bowel Disease Management and Patient Care

Brian Bressler - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Inflammatory bowel disease

Methadone hydrochloride

Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-NaiVE Patients: Pooled Analysis of Phase III Studies

Donald M. Jensen - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Faldaprevir-sodium

The Impact of Endoscopist Case Volume on ERCP Outcomes: Experience At a Canadian Tertiary Centre

Pernilla -Souza - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Pancreatitis

N/A

Meta-Analysis of Sequential vs. Standard Triple Therapy for Helicobacter pylori Eradication: Final Results of a Cochrane Systematic Review

Adrian G. McNicholl - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Peptic ulcer

Biaxin

Community H. pylori Project Treatment Trial Results From the Canadian Arctic

Laura Aplin - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Biaxin

Effect of Temperature, Time and Freeze/Thaw Cycles on the Stability of Fecal Hemoglobin Using Five Commercial Fecal Immunochemical Test (FIT) Methods and One Guaiac Method

Nancy N. Baxter - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Interval Cancers After Screening Colonoscopy Performed in the Setting of a Continuous Quality Improvement Program With Monitoring of Endoscopist Performance Are Associated With Low Endoscopist Adenoma Detection Rate

S. Elizabeth McGregor - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Percutaneous SPYGLASS Cholangioscopy for Assessment of Biliary Strictures

Pernilla M. D'Souza - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

N/A

Focus: the Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of IBD

Andrew M. Round - Digestive Disease Week (DDW) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Filters

28841 Abstracts